Cargando…

Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC

BACKGROUND: We derived estimates of overdiagnosis by polygenic risk groups and examined whether polygenic risk-stratified screening for prostate cancer reduces overdiagnosis. METHODS: We calculated the polygenic risk score based on genotypes of 66 known prostate cancer loci for 4967 men from the Fin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pashayan, Nora, Pharoah, Paul DP, Schleutker, Johanna, Talala, Kirsi, Tammela, Teuvo LJ, Määttänen, Liisa, Harrington, Patricia, Tyrer, Jonathan, Eeles, Rosalind, Duffy, Stephen W, Auvinen, Anssi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651137/ https://www.ncbi.nlm.nih.gov/pubmed/26291059 http://dx.doi.org/10.1038/bjc.2015.289

Ejemplares similares

Prostate cancer risk prediction using a polygenic risk score
por: Sipeky, Csilla, et al.
Publicado: (2020)

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kaapu, Kalle J, et al.
Publicado: (2016)

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial
por: Veitonmäki, Thea, et al.
Publicado: (2016)

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
por: Murtola, Teemu J., et al.
Publicado: (2018)

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
por: Siltari, Aino, et al.
Publicado: (2020)

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kinnunen, Pete T. T., et al.
Publicado: (2017)

Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men
por: Kaapu, Kalle J., et al.
Publicado: (2018)

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis
por: Pashayan, Nora, et al.
Publicado: (2015)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer
por: Talala, Kirsi, et al.
Publicado: (2020)

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
por: Salminen, Jukka K., et al.
Publicado: (2022)

Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time
por: Pylväläinen, Juho, et al.
Publicado: (2019)

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level
por: Peltomaa, Antti I., et al.
Publicado: (2022)

Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease
por: Sipeky, Csilla, et al.
Publicado: (2021)

PALB2 variants in hereditary and unselected Finnish Prostate cancer cases
por: Pakkanen, Sanna, et al.
Publicado: (2009)

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data
por: Booth, Neill, et al.
Publicado: (2019)

Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation
por: Neupane, Subas, et al.
Publicado: (2021)

MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families
por: Fischer, Daniel, et al.
Publicado: (2015)

European randomized study of prostate cancer screening: first-year results of the Finnish trial
por: Määttänen, L, et al.
Publicado: (1999)

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial
por: Veitonmäki, T, et al.
Publicado: (2014)

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
por: Murtola, T J, et al.
Publicado: (2009)

False-positive screening results in the Finnish prostate cancer screening trial
por: Kilpeläinen, T P, et al.
Publicado: (2010)

Is the Prevalence of Overactive Bladder Overestimated? A Population-Based Study in Finland
por: Tikkinen, Kari A.O., et al.
Publicado: (2007)

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial
por: Määttänen, L, et al.
Publicado: (2007)

Polygenic susceptibility to prostate and breast cancer: implications for personalised screening
por: Pashayan, N, et al.
Publicado: (2011)

Missingness in the expanded prostate cancer index short form (EPIC-26) – prevalence, patterns, and explanatory factors
por: Talvitie, Anna-Maija, et al.
Publicado: (2023)

Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
por: Callender, Tom, et al.
Publicado: (2019)

What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women
por: Agarwal, Arnav, et al.
Publicado: (2014)

Assessing Interactions of Two Loci (rs4242382 and rs10486567) in Familial Prostate Cancer: Statistical Evaluation of Epistasis
por: Chen, Li-Sheng, et al.
Publicado: (2014)

Is the incidence of hypospadias increasing? Analysis of Finnish hospital discharge data 1970-1994.
por: Aho, M, et al.
Publicado: (2000)

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening
por: Pashayan, N, et al.
Publicado: (2009)

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene
por: Mattila, Henna, et al.
Publicado: (2011)

Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia
por: Pashayan, N, et al.
Publicado: (2006)

Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia
por: Pashayan, N, et al.
Publicado: (2006)

HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005
por: Köninki, Katri, et al.
Publicado: (2009)

The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam
por: Remmers, Sebastiaan, et al.
Publicado: (2023)

Cancer incidence in the vicinity of Finnish nuclear power plants: an emphasis on childhood leukemia
por: Heinävaara, Sirpa, et al.
Publicado: (2009)

Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE)
por: Nikkilä, Atte, et al.
Publicado: (2018)

Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE)
por: Nikkilä, Atte, et al.
Publicado: (2020)

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
por: Peltomaa, A. I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qissckegindb91os718uv43k3t